Jefferies Boosts Target on Aegerion (AEGR) to $29 Ahead of Juxtapid Commercialization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Analyst Bullish as Aegerion (AEGR) Drug Approved with Broad Label
December 26, 2012 9:23 AM ESTOn Monday Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced that the U.S. Food & Drug Administration approved JUXTAPID (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments. In response, Leerink Swann reiterated an Outperform rating on Aegerion and raised its price target to $30.00 (from $25.00).
"Lead agent Juxtapid (lomitapide) is a smallmolecule microsomal triglyceride transfer protein (MTP) inhibitor with the unique ability to limit... More
